OCGN Oct 2024 3.000 call
- GlobeNewswire
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and
- GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “Each clinical milestone achieved by OCU400 brings us closer to providing a o
- Zacks
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.
